Read More

argenx Announces Preliminary Q4 And FY23 Results: Expects 4Q23 Total Revenue Of ~$374M Vs $ 384.95M Est.; And FY23 Revenue Of ~$1.2B Vs. $1.22B Est.; Preliminary Unaudited December 31, 2023 Cash, Cash Equivalents, And Current Financial Assets Of ~$3.2B

Today, argenx also announced preliminary* global net VYVGART revenues for the fourth quarter and full-year 2023 of approximately $374 million and $1.2 billion, respectively. As of December

ARGX

Read More

Annexon Outlines 2024 Priorities With Late-Stage Clinical Milestones Across Upstream Complement Portfolio For Autoimmune, Ophthalmic And Neurodegenerative Diseases; Says Recent $125M Financing Extends Operating Runway Into Q2 2026

ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in Geographic Atrophy

ANNX

Read More

Ascendis Pharma Introduces Vision 2030; Preliminary Unaudited December 31, 2023 Cash, Cash Equivalents, And Marketable Securities Of ~€400M; Full Year 2024 SKYTROFA Revenue Expected To Be €320M-€340M

Strategic roadmap to achieve blockbuster status for multiple products and expandthe Company's engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND)

ASND

Read More

Alnylam Announces Preliminary Q4 And FY23 Global Net Product Revenues And Provides Additional Updates; Q4 Net Product Revenues For ONPATTRO And AMVUTTRA ~$79M And $175M; Q4 Net Product Revenues For GIVLAARI And OXLUMO ~$59M And $33M

– Achieved Full Year 2023 Preliminary Global Net Product Revenues of $1,241 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 39% Annual Growth (39% Using Constant Exchange

ALNY

Read More

Amicus Therapeutics Reports Preliminary 2023 Revenue And Provides 2024 Strategic Outlook; Q4 Revenue ~$115.1M Vs $112.25M Est.; Sees FY23 Revenue Of ~$399.4M Vs $396.45M Est.; Co Sees FY24 As First Full Year Of Achieving Non-GAAP Profitability

Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "Last year was an incredible year for Amicus highlighted by the continued double-digit growth of Galafold sales and the global

FOLD

Read More

Exelixis Announces Preliminary FY23 Financial Results, Provides 2024 Financial Guidance, And Outlines Key Priorities And Milestones For 2024; Sees FY23 Revenue Of $1.83B Vs $1.84B Est.; Sees FY24 Revenue $1.825B-$1.925B Vs $2.06B Est.

Preliminary Fiscal Year 2023 Financial Results & 2024 Financial GuidanceExelixis is providing the following preliminary unaudited 2023 financial results and financial guidance for 2024: Fiscal Year 2023Fiscal

EXEL